CV Sciences Inc

CV Sciences reports a tough Q1 2026 with sales decline, modest EBITDA loss, and debt restructuring, yet maintains stable margins and cuts expenses to boost resilience and future growth in the personal care sector.

CV Sciences releases Q1 2026 results, spotlighting hemp‑derived +PlusCBD and diverse wellness brands, offering insight into its growth and market resilience.

CV Sciences Inc. sees volatile OTC stock, blending consumer personal‑care and specialty pharma; investors watch its low‑priced, loss‑bearing outlook.